Renowned Physician and Key Opinion Leader to Provide Current Board with
Unique and Valuable Medical and Research Perspective
BEVERLY, MA and TORONTO, Jan. 19 /CNW/ - Hamilton Thorne Ltd. (TSX-V:
HTL), a leading provider of advanced laser systems for the regenerative
medicine, developmental biology, stem cell research and fertility
markets, today announced that David Sable, M.D., Portfolio Manager of
Special Situations Life Sciences Fund, has joined Hamilton Thorne's
Board of Directors.
"Special Situations is a leader amongst U.S. life sciences funds and one
of our most supportive investors. We are privileged to have Dr. Sable
join our Board of Directors and provide us with his valuable insight,
not only as a portfolio manager, but also as a physician and expert in
cell biology," said Meg Spencer, Chief Executive Officer of Hamilton
Thorne Ltd. "Dr. Sable's unique perspective and guidance will be
especially helpful as we continue to launch groundbreaking life
sciences products into new and important research markets such as
cancer and developmental biology."
In addition to his current position as Portfolio Manager at the Special
Situations Life Sciences Fund, Dr. Sable was Director of the Institute
for Reproductive Medicine and Science at Saint Barnabas Medical Center
in New Jersey. He is board certified in both obstetrics and gynecology
and reproductive endocrinology, and has held academic positions at
Harvard Medical School and the Columbia University Graduate School of
Arts and Sciences. Dr. Sable is a graduate of the Wharton School and
the University Of Pennsylvania School Of Medicine.
"Hamilton Thorne is well positioned to become a leading life science
solutions company that can help both its academic and commercial
customers speed the research and discovery process for diseases such
as Parkinson's, Alzheimer's, infertility and macular degeneration,"
said Dr. David Sable, Director of Hamilton Thorne and Portfolio Manager
of Special Situations Life Sciences Fund. "I look forward to joining
Hamilton Thorne's Board of Directors and being part of the Company's
continued growth and expansion, as the new products launched in late
2010, such as the Staccato™ and Stiletto™ laser systems, gain
additional market adoption in 2011."
Dr. Sable joins Hamilton Thorne's current Board of Directors of Meg
Spencer, Chairman of the Board and Chief Executive Officer of Hamilton
Thorne; Diarmaid H. Douglas-Hamilton, Director, Corporate Secretary and
Chief Technology Officer of Hamilton Thorne; Dean Gendron, Director,
Member of Compensation Committee and Audit Committee; Bruno Maruzzo,
Director and Chair of Audit Committee; Scott A Pearson, Director and
Member of Audit Committee; Robert J. Potter, Director and Chair of
Compensation Committee; and Daniel K. Thorne, Director and Member of
The Company also announced that it has granted Dr. Sable 150,000 stock
options to purchase in pursuant of the Company's incentive stock option
plan. The options are exercisable at Cdn$0.215 per share, vest over
three years, and expire ten years from the date of grant.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading provider of advanced laser systems for the
regenerative medicine, and stem cell research markets. Hamilton
Thorne's lead products, the ZILOS-tk™ and XYClone® laser systems,
attach to standard inverted microscopes and operate as robotic
micro-surgeons, significantly reducing time and increasing efficiency
in key in-vitro fertilization, stem cell, and regenerative medical
research applications. The new Staccato™ and Stiletto™ laser systems
are designed to broaden the Company's markets and offer significant
advantages to developmental biology, cancer research and advanced cell
Hamilton Thorne's growing customer base includes pharmaceutical
companies, biotechnology companies, fertility clinics, university
research centers, and other commercial and academic research
establishments worldwide. Current customers include world-leading
research labs such as Harvard University, MIT, Yale, McGill University,
DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis,
Pfizer, Oxford University, and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services
provider (as that term is defined in the policies of the exchange),
accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking
statements. This information is based on current expectations that are
subject to significant risks and uncertainties that are difficult to
predict. Actual results might differ materially from results suggested
in any forward-looking statements. The Company assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward
looking-statements unless and until required by securities laws
applicable to the Company. Additional information identifying risks and
uncertainties is contained in filings by the Company with the Canadian
securities regulators, which filings are available at www.sedar.com.
SOURCE Hamilton Thorne Ltd.
For further information:
David Wolf, President
Hamilton Thorne Ltd.
Lisa Rivero, Director of Corporate Communications
Hamilton Thorne Ltd.
The Equicom Group